Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - quofenix
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp27f53ce7e817ea56aac44769c7b5a3bb
identifier: http://ema.europa.eu/identifier
/EU/1/19/1393/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Quofenix 300 mg powder for concentrate for solution for infusion
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-27f53ce7e817ea56aac44769c7b5a3bb
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/19/1393/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - quofenix
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Quofenix is an antibiotic that contains the active substance delafloxacin. It belongs to a group of medicines called fluoroquinolones.
It is used to treat adults with serious short-term infections caused by certain bacteria when usual antibiotics cannot be used or have not worked:
It works by blocking bacteria enzymes needed to copy and to repair their DNA. By blocking these enzymes, Quofenix kills bacteria that cause the infection.
You must not be given Quofenix:
Warnings and precautions Before you are given this medicine You should not be given fluoroquinolone/quinolone antibacterial medicines, including Quofenix, if you have experienced any serious adverse reaction in the past when taking a quinolone or fluoroquinolone. In this situation, you should inform your doctor as soon as possible.
When you are given this medicine
Talk to your doctor or pharmacist or nurse before you are given Quofenix if:
If you feel sudden, severe pain in your abdomen, chest or back, which can be symptoms of aortic aneurysm and dissection, go immediately to an emergency room. Your risk may be increased if you are being treated with systemic corticosteroids.
If you start experiencing a rapid onset of shortness of breath, especially when you lie down flat in your bed, or you notice swelling of your ankles, feet or abdomen, or a new onset of heart palpitations (sensation of rapid or irregular heartbeat), you should inform a doctor immediately.
Prolonged, disabling and potentially irreversible serious side effects Fluoroquinolone/quinolone antibacterial medicines have been associated with very rare but serious side effects, some of them being long lasting (continuing months or years), disabling or potentially irreversible. This includes tendon, muscle and joint pain of the upper and lower limbs, difficulty in walking, abnormal sensations such as pins and needles, tingling, tickling, numbness or burning (paraesthesia), sensory disorders including impairment of vision, taste and smell, and hearing, depression, memory impairment, severe fatigue, and severe sleep disorders. If you experience any of these side effects after receiving Quofenix, contact your doctor immediately prior to continuing treatment. You and your doctor will decide on continuing the treatment considering also an antibiotic from another class.
Children and adolescents This medicine must not be used in children and adolescents, as it has not been studied enough in these groups.
Other medicines and Quofenix Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. There are no data concerning an interaction of intravenous delafloxacin with multivitamins, other supplements or didanosine. However, Quofenix should not be given together with any solution containing substances such as calcium and magnesium, through the same intravenous line.
Pregnancy and breast-feeding Quofenix must not be used if you are pregnant or breast-feeding. Quofenix must not be used in women of childbearing potential not using contraception.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, tell your doctor before you are given this medicine. If you might become pregnant you have to use effective contraception during treatment with Quofenix.
Driving and using machines Quofenix can make you feel dizzy and lightheaded. Do not drive, operate machinery, or do other activities that require mental alertness or coordination until you know how Quofenix affects you.
Quofenix contains cyclodextrin This medicine contains 2480 mg of sulfobutylbetadex sodiumin each vial.
Quofenix contains sodium This medicine contains 175 mg of sodium (main component of cooking salt) in each vial. This is equivalent to 8.8% of the recommended maximum daily dietary intake of sodium for an adult.
Quofenix will be given to you by a nurse or doctor via an infusion (drip) into a vein.
You will be given one infusion of Quofenix, containing 300 mg of the medicine, twice a day between 5 and 14 days for skin infections and between 5 and 10 days for pneumonia, at the discretion of your doctor. Each infusion will last about an hour. Your doctor will decide how many days treatment is needed.
Tell your doctor if you suffer from kidney problems because your dose may need to be adjusted.
If you have any further questions on the use of this medicine, ask your doctor.
If you are given more Quofenix than you should Tell your doctor or nurse immediately if you are concerned that you may have been given too much Quofenix.
If you miss a dose of Quofenix Tell your doctor or nurse immediately if you are concerned that you may have missed a dose. If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Please, inform your doctor or nurse immediately if you get any of these symptoms, as the medicine should be stopped and you may need urgent medical attention:
Other side effects may include:
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1000 people):
Very rare cases of long lasting (up to months or years) or permanent adverse drug reactions, such as tendon inflammations, tendon rupture, joint pain, pain in the limbs, difficulty in walking, abnormal sensations such as pins and needles, tingling, tickling, burning, numbness or pain (neuropathy), depression, fatigue, sleep disorders, memory impairment, as well as impairment of hearing, vision, and taste and smell have been associated with administration of quinolone and fluoroquinolone antibiotics, in some cases irrespective of pre-existing risk factors.
Cases of an enlargement and weakening of the aortic wall or a tear in the aortic wall (aneurysms and dissections), which may rupture and may be fatal, and of leaking heart valves have been reported in patients receiving fluoroquinolones. See also section 2. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton or blister after EXP . The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions if kept unopened in the original container.
After reconstitution: Chemical and physical in-use stability has been demonstrated for 24 hours at to 25 C or at 2 to 8 C. From a microbiological point of view, the product should be used immediately after reconstitution and dilution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 C, unless reconstitution and dilution has taken place in controlled and validated aseptic conditions.
Do not freeze.
What Quofenix contains
What Quofenix looks like and contents of the pack Quofenix powder for concentrate for solution for infusion is provided in 20 ml clear glass vial. The vial contains light yellow to tan cake powder. It is available in packs containing 10 vials.
Marketing Authorisation Holder A. Menarini Industrie Farmaceutiche Riunite s.r.l. Via Sette Santi 3 50131 Florence Italy
Manufacturer Patheon Italia S.p.A. 2 Trav. SX Via Morolense 5 03013 Ferentino (FR) Italy
or
AlfaSigma 1 Via Enrico Fermi 65020 Alanno (PE) Italy
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
Belgi /Belgique/Belgien Menarini Benelux NV/SA T l/Tel: + 32 (0)2 721 4Lietuva UAB BERLIN-CHEMIE MENARINI BALTIC
Tel: +370 52 691
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-27f53ce7e817ea56aac44769c7b5a3bb
Resource Composition:
Generated Narrative: Composition composition-en-27f53ce7e817ea56aac44769c7b5a3bb
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/19/1393/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - quofenix
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp27f53ce7e817ea56aac44769c7b5a3bb
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp27f53ce7e817ea56aac44769c7b5a3bb
identifier:
http://ema.europa.eu/identifier
/EU/1/19/1393/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Quofenix 300 mg powder for concentrate for solution for infusion
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en